Cytotoxic chemotherapy remains a cornerstone of cancer treatment despite the advent of targeted therapies and immunotherapy. These agents kill rapidly dividing cells by interfering with DNA synthesis, replication, or cell division, but their lack of selectivity for cancer cells results in significant toxicity to normal proliferating tissues.
What Is Cytotoxic Chemotherapy?
Cytotoxic agents are classified by their mechanism of action and cell cycle specificity. Cell cycle-specific agents are active during particular phases of the cell cycle, while cell cycle-nonspecific agents kill cells regardless of their proliferative state. Combination chemotherapy using agents with different mechanisms and non-overlapping toxicities improves efficacy and reduces resistance.
Drug Classes and Mechanisms
Alkylating agents including cyclophosphamide, cisplatin, and carmustine add alkyl groups to DNA bases, causing cross-linking and strand breaks that prevent replication and transcription. Cyclophosphamide requires hepatic activation to its active metabolite and is used in lymphomas, breast cancer, and as an immunosuppressant. Cisplatin and its analogues carboplatin and oxaliplatin form platinum-DNA adducts and are active in testicular, ovarian, and lung cancers.
Antimetabolites mimic natural metabolites required for DNA and RNA synthesis. Methotrexate inhibits dihydrofolate reductase, depleting reduced folates needed for nucleotide synthesis. 5-fluorouracil (5-FU) inhibits thymidylate synthase through its active metabolite. Capecitabine is an oral prodrug of 5-FU. Gemcitabine competes with deoxycytidine triphosphate for incorporation into DNA, causing chain termination. These agents are cell cycle-specific, targeting S phase.
Plant alkaloids include taxanes (paclitaxel, docetaxel) that stabilize microtubules, preventing mitotic spindle breakdown and arresting cells in M phase. Vinca alkaloids (vincristine, vinblastine) bind tubulin and prevent microtubule formation, also causing M phase arrest. Etoposide inhibits topoisomerase II, preventing DNA religation.
Antitumor antibiotics include doxorubicin, which intercalates DNA, inhibits topoisomerase II, and generates free radicals. Cumulative dose-dependent cardiotoxicity limits doxorubicin use. Bleomycin causes DNA strand breaks through free radical generation and is associated with pulmonary fibrosis.
Topoisomerase inhibitors include irinotecan (topoisomerase I inhibitor) and etoposide (topoisomerase II inhibitor). These agents trap topoisomerase-DNA complexes, leading to DNA damage during replication.
Therapeutic Uses
Cytotoxic chemotherapy is used in curative intent for hematologic malignancies (leukemias, lymphomas) and certain solid tumors (testicular cancer, gestational trophoblastic disease). In many advanced solid tumors, chemotherapy provides palliative benefit, improving survival and quality of life. Neoadjuvant chemotherapy is given before surgery to reduce tumor size, while adjuvant chemotherapy eradicates micrometastatic disease after definitive local therapy.
Adverse Effects
Myelosuppression is the most common dose-limiting toxicity, causing neutropenia, anemia, and thrombocytopenia. Gastrointestinal toxicity includes nausea, vomiting, mucositis, and diarrhea. Alopecia occurs with many agents. Specific toxicities include cisplatin nephrotoxicity and peripheral neuropathy, doxorubicin cardiotoxicity, bleomycin pulmonary fibrosis, and cyclophosphamide hemorrhagic cystitis.
Key Clinical Considerations
Dose adjustments are required based on organ function, particularly renal and hepatic. Growth factor support (G-CSF) reduces febrile neutropenia risk. Antiemetic prophylaxis is essential, particularly with highly emetogenic regimens. Fertility preservation should be discussed before initiating therapy. Long-term survivors require monitoring for late effects including secondary malignancies and organ dysfunction.
Conclusion
Cytotoxic chemotherapy remains a vital component of cancer treatment, particularly in combination regimens. Despite their toxicity, these agents cure many patients with disseminated cancer and provide meaningful benefit across a wide range of malignancies.
